Team

At InnoMedica, experienced entrepreneurs and managers work side-by-side with university graduates. InnoMedica’s goal is to involve the entire team as shareholders and to develop an entrepreneurial spirit among its employees. Today the InnoMedica team consists of 27 employees – all with higher education, whereby the strong technical focus of InnoMedica is reflected in the 18 employees with degrees in biochemistry, chemistry or medicine. The high level of expertise in this core area is an important requirement for our success.

Organization Chart InnoMedica Holding AG
Organization Chart InnoMedica Schweiz AG

Peter Halbherr
Peter Halbherr
Dr. phil. et phil. Universites of Zürich and Paris

Dr. Peter Halbherr has been with InnoMedica since 2001. He was member of the Board since 2002, acts as delegate of the Board and was elected chairman by the general assembly 2018. As a business and personnel consultant in the pharmaceutical, IT and financial sector, Dr. Halbherr provides expertise in building companies and access to a valuable network of executives, startups and financing.

Dr. Halbherr founded the consulting firm IPAG Inter Personal AG in 1988, which is active in management selection and management consultancy. Under his direction IPAG Inter Personal AG provided the initial funding for InnoMedica and served as incubator for the Talidox project. He is partner of BTS Business Technology & Services GmbH, which is active in software in Business Administration. Dr. Halbherr developed sqlFinance an Enterprise Resource Planning software, which InnoMedica uses today for accounting, payroll, purchasing and delivery/sales as well as for pharmaceutical GMP production.

Dr. Halbherr’s doctoral dissertation on career patterns, a DESS Psychology in Industrial Psychology, was a research project on careers and corporate culture in Paris (1979 – 1983, published as IBM – Mythe et Mythe et Réalité) resulted in a Dr. phil. et phil. degree from the Universities of Zurich and Paris. Previously, he studied psychology and graduated from the University of Zurich.

Chairman and Delegate of the Board, General Manager
Denis Bron
Denis Bron
Dr. med., University of Basel

Dr. med. Denis Bron has operated since 2005 as InnoMedica’s Medical Advisor and joined the Board of InnoMedica in 2018. He brings a broad network in the medical sector as well as experience in dealing with doctors and hospitals. Dr. Bron also holds an earlier patent which he introduced in 2010 into the company based on a targeting approach for pharmaceutical active ingredients.

Dr. Bron is chief of Aviation Medicine for the Air Force of the Aeromedical Institute FAI and directs the Aeromedical Centre (AeMC) in Dübendorf. He previously worked in the field of neurology at Harvard Medical School in Boston, the University Hospital Basel, and the Cantonal hospital in Aarau. Dr. Bron graduated from the University of Basel in 1997 with a degree in medical studies. In addition to his training in the hospital, he holds the certificate of EMG-competence, completed additional leadership courses and graduated in 2013 as a European Human Factor specialist.

Member of the Board, Vice-Chairman
Urs Wälchli
Urs Wälchli
Prof. Dr. rer. oec., University of Bern

Prof. Dr. Urs Wälchli was elected member of the Board at the General assemby in 2019. He has advised the Board of Directors of InnoMedica since 2018, primarily on governance, strategy and financial issues. He is a visiting professor at the Simon Business School of the University of Rochester, New York, Deputy Academic Director of the Rochester-Bern Executive Program and SFI Adjunct Professor. The focus of his research, teaching and consulting activities is the financing and management of innovative companies.
Urs Wälchli studied economics at the University of Bern, where he also completed his doctorate on «Corporate Governance of Swiss Boards of  Directors». He has researched and taught at various American universities (NYU, Wharton, Purdue University) and was assistant professor at the University of Bern from 2008 to 2014.

Memeber of the Board
Noboru Yamazaki
Noboru Yamazaki
Dr. rer. nat.

Dr. Noboru Yamazaki was elected at the 2013 Annual General Meeting to the Board of InnoMedica. His years of research experience in the field of active targeting and his solid experience in patent applications are key to the success of the InnoMedica Talidox project.

He founded the company Yamazaki DDS Co., Ltd. to develop new applications with an active targeting drug delivery system. This new technology results from his research while working as group leader of the NanoBio-Medicine Technology Laboratory at the Nanotechnology Research Institute of the National Institute of Advanced Industrial Science and Technology (AIST) in Japan. Dr. Yamazaki worked with scientists from the Chemistry Department of the University of Colorado and the Max Planck Institute of Experimental Medicine and was director of research grants at the International Human Frontier Science Program Organization. After receiving his PhD in Biology from the University of Hamburg and postdoctoral research at Mitsubishi Kasei Institute of Life Sciences, Research Officer of the Industrial Products Research Institute, he began his career at AIST as Head of Materials Design Laboratory.

Member of the Board, Chief Technology Office
Stéfan Halbherr
Stéfan Halbherr
PhD, University of Bern
Country Manager, Research and Development, Management
Pascal Halbherr
Pascal Halbherr
MSc Biochemistry, University of Bern

Pascal Halbherr, elder son of Dr. Peter Halbherr. Head of Production, began working at InnoMedica in Autumn 2012. His interest in the latest research in biochemistry and his readiness to explore novel concepts led to the launch of the collaboration with Dr. Yamazaki and form the starting point of the Talidox project.

Along with Stéphane Gumy, he developed the GMP production at the Marly Innovation Center and adapted the production processes from pure research to industrial scales. He graduated from the University of Bern with a Bachelor’s degree in Biochemistry and a Master’s degree in Immunology (Thromboxane A2 acts as tonic immunoregulator by preferential disruption of low-avidity CD4+ T cell-dendritic cell interactions).

Manufacturing, Project Leader, Management
Jonas Zeller
Jonas Zeller
Dr. rer. oec., University of Bern

Dr. Jonas Zeller joined InnoMedica in 2013 as Head of Finance and Administration. He brings experience in Financial Management, and is a lecturer of Business Valuation at the University of Bern and the Bern-Rochester Executive MBA program.

He obtained a doctorate from the Institute of Financial Management at the University of Bern, where his research examined the interaction between age and economic efficiency of enterprises. Prior to his doctoral thesis, he had a role as an analyst in the Economic Research Department at Credit Suisse in Zürich. His graduate studies were at the University of Bern and the Simon Graduate School of Business at the University of Rochester in New York.

Finance & Administration, Management
Andrea Zurkirchen
Andrea Zurkirchen
lic. phil., University of Zürich

Andrea Zurkirchen became part of the InnoMedica team in summer 2012 due to her consulting role with IPAG Inter Personal AG and the merger with Yamazaki-DDS Co., Ltd. She gained experience in personnel management and administration, as well as communications, marketing and sales, through work with IPAG Inter Personal AG and BTS Business Technology & Services GmbH. As Chief of Staff at InnoMedica, she is responsible for the organisation and legal implementation of the financing rounds, looks after shareholder contacts and is also responsible for external communication in addition to her personnel tasks.

She studied psychology at the University of Zurich, specializing in biopsychology and behavioral therapy. In her thesis she examined the connection between psychological and biological reactions to stress.

Communicationl, HR, Legal & Compliance, Staff
Stèphane Gumy
Stèphane Gumy
Chemist Degree, Fribourg
Qualified Person, Staff
Philipp Halbherr
Philipp Halbherr
Dr. oec., University of Zurich
Financial Advisor